Effect of trimerization motifs on quaternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoprotein

Virology

Volumn 395, Issue 1, 2009, Pages 33-44

  Du, Sean X ^a   Idiart, Rebecca J ^a   Mariano, Ellaine B ^a   Chen, Helen ^a   Jiang, Peifeng ^b   Xu, Li ^a   Ostrow, Kristin M ^a   Wrin, Terri ^c   Phung, Pham ^c   Binley, James M ^b   Petropoulos, Christos J ^c   Ballantyne, John A ^d   Whalen, Robert G ^a  

^a MAXYGEN INC   (United States)

^b TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

^c MONOGRAM BIOSCIENCES   (United States)

^d Aldevron LLC   (United States)

Author keywords

ATCase; CD4; Envelope; GCN; HIV 1; Immunization; Monoclonal antibody; Neutralizing antibody; T4 fibritin; Trimerization motifs; Vaccine

Indexed keywords

ASPARTATE CARBAMOYLTRANSFERASE; CD4 ANTIBODY; GLYCOPROTEIN GP 140; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGENICITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL STRAIN HEK293; CONTROLLED STUDY; DISULFIDE BOND; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; EXPRESSION VECTOR; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; IMMUNOGENICITY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEIN PURIFICATION; PROTEIN QUATERNARY STRUCTURE; VIRUS MUTATION; VIRUS NEUTRALIZATION; WESTERN BLOTTING;

AMINO ACID MOTIFS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODY FORMATION; ANTIGENS, VIRAL; CELL LINE; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ANTIBODIES; HUMANS; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, QUATERNARY; RABBITS;

ESCHERICHIA COLI; HUMAN IMMUNODEFICIENCY VIRUS 1; ORYCTOLAGUS CUNICULUS;

EID: 71849114139     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2009.07.042     Document Type: Article

References (75)

1. Arthos J., Deen K.C., Chaikin M.A., Fornwald J.A., Sathe G., Sattentau Q.J., Clapham P.R., Weiss R.A., McDougal J.S., Pietropaolo C., et al. Identification of the residues in human CD4 critical for the binding of HIV. Cell 57 3 (1989) 469-481
2. Baba T.W., Liska V., Hofmann-Lehmann R., Vlasak J., Xu W., Ayehunie S., Cavacini L.A., Posner M.R., Katinger H., Stiegler G., Bernacky B.J., Rizvi T.A., Schmidt R., Hill L.R., Keeling M.E., Lu Y., Wright J.E., Chou T.C., and Ruprecht R.M. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6 2 (2000) 200-206
3. Barbas III C.F., Collet T.A., Amberg W., Roben P., Binley J.M., Hoekstra D., Cababa D., Jones T.M., Williamson R.A., Pilkington G.R., et al. Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries. J. Mol. Biol. 230 3 (1993) 812-823
4. Beddows S., Schulke N., Kirschner M., Barnes K., Franti M., Michael E., Ketas T., Sanders R.W., Maddon P.J., Olson W.C., and Moore J.P. Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J. Virol. 79 14 (2005) 8812-8827
5. Binley J.M., Sanders R.W., Clas B., Schuelke N., Master A., Guo Y., Kajumo F., Anselma D.J., Maddon P.J., Olson W.C., and Moore J.P. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J. Virol. 74 2 (2000) 627-643
6. Binley J.M., Wrin T., Korber B., Zwick M.B., Wang M., Chappey C., Stiegler G., Kunert R., Zolla-Pazner S., Katinger H., Petropoulos C.J., and Burton D.R. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78 23 (2004) 13232-13252
7. Binley J.M., Lybarger E.A., Crooks E.T., Seaman M.S., Gray E., Davis K.L., Decker J.M., Wycuff D., Harris L., Hawkins N., Wood B., Nathe C., Richman D., Tomaras G.D., Bibollet-Ruche F., Robinson J.E., Morris L., Shaw G.M., Montefiori D.C., and Mascola J.R. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J. Virol. 82 23 (2008) 11651-11668
8. Bower J.F., Li Y., Wyatt R., and Ross T.M. HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies. Vaccine 24 26 (2006) 5442-5451
9. Burton D.R., Barbas III C.F., Persson M.A., Koenig S., Chanock R.M., and Lerner R.A. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc. Natl. Acad. Sci. U.S.A. 88 22 (1991) 10134-10137
10. Burton D.R., Desrosiers R.C., Doms R.W., Koff W.C., Kwong P.D., Moore J.P., Nabel G.J., Sodroski J., Wilson I.A., and Wyatt R.T. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5 3 (2004) 233-236
11. Byrn R.A., Mordenti J., Lucas C., Smith D., Marsters S.A., Johnson J.S., Cossum P., Chamow S.M., Wurm F.M., Gregory T., et al. Biological properties of a CD4 immunoadhesin. Nature 344 6267 (1990) 667-670
12. Calarese D.A., Scanlan C.N., Zwick M.B., Deechongkit S., Mimura Y., Kunert R., Zhu P., Wormald M.R., Stanfield R.L., Roux K.H., Kelly J.W., Rudd P.M., Dwek R.A., Katinger H., Burton D.R., and Wilson I.A. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300 5628 (2003) 2065-2071
13. Carotenuto P., Looij D., Keldermans L., de Wolf F., and Goudsmit J. Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection. Aids 12 13 (1998) 1591-1600
14. Chakrabarti B.K., Kong W.P., Wu B.Y., Yang Z.Y., Friborg J., Ling X., King S.R., Montefiori D.C., and Nabel G.J. Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. J. Virol. 76 11 (2002) 5357-5368
15. Chen B., Cheng Y., Calder L., Harrison S.C., Reinherz E.L., Skehel J.J., and Wiley D.C. A chimeric protein of simian immunodeficiency virus envelope glycoprotein gp140 and Escherichia coli aspartate transcarbamoylase. J. Virol. 78 9 (2004) 4508-4516
16. Dey A.K., David K.B., Klasse P.J., and Moore J.P. Specific amino acids in the N-terminus of the gp41 ectodomain contribute to the stabilization of a soluble, cleaved gp140 envelope glycoprotein from human immunodeficiency virus type 1. Virology 360 1 (2007) 199-208
17. Dey A.K., David K.B., Ray N., Ketas T.J., Klasse P.J., Doms R.W., and Moore J.P. N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus. Virology 372 1 (2008) 187-200
18. Du S.X., Xu L., Viswanathan S., and Whalen R.G. Inhibition of V3-specific cleavage of recombinant HIV-1 gp120 produced in Chinese hamster ovary cells. Protein Expr. Purif. 59 2 (2008) 223-231
19. Earl P.L., Broder C.C., Long D., Lee S.A., Peterson J., Chakrabarti S., Doms R.W., and Moss B. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. J. Virol. 68 5 (1994) 3015-3026
20. Else A.J., and Herve G. A microtiter plate assay for aspartate transcarbamylase. Anal. Biochem. 186 2 (1990) 219-221
21. Frost S.D., Liu Y., Pond S.L., Chappey C., Wrin T., Petropoulos C.J., Little S.J., and Richman D.D. Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B. J. Virol. 79 10 (2005) 6523-6527
22. Grundner C., Pancera M., Kang J.M., Koch M., Sodroski J., and Wyatt R. Factors limiting the immunogenicity of HIV-1 gp120 envelope glycoproteins. Virology 330 1 (2004) 233-248
23. Grundner C., Li Y., Louder M., Mascola J., Yang X., Sodroski J., and Wyatt R. Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins. Virology 331 1 (2005) 33-46
24. Haas J., Park E.C., and Seed B. Codon usage limitation in the expression of HIV-1 envelope glycoprotein. Curr. Biol. 6 3 (1996) 315-324
25. Helmstaedt K., Krappmann S., and Braus G.H. Allosteric regulation of catalytic activity: Escherichia coli aspartate transcarbamoylase versus yeast chorismate mutase. Microbiol. Mol. Biol. Rev. 65 3 (2001) 404-421 table of contents
26. Herrera C., Klasse P.J., Michael E., Kake S., Barnes K., Kibler C.W., Campbell-Gardener L., Si Z., Sodroski J., Moore J.P., and Beddows S. The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles. Virology 338 1 (2005) 154-172
27. Hessell A.J., Poignard P., Hunter M., Hangartner L., Tehrani D.M., Bleeker W.K., Parren P.W., Marx P.A., and Burton D.R. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. (2009)
28. Hofmann-Lehmann R., Vlasak J., Rasmussen R.A., Smith B.A., Baba T.W., Liska V., Ferrantelli F., Montefiori D.C., McClure H.M., Anderson D.C., Bernacky B.J., Rizvi T.A., Schmidt R., Hill L.R., Keeling M.E., Katinger H., Stiegler G., Cavacini L.A., Posner M.R., Chou T.C., Andersen J., and Ruprecht R.M. Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. J. Virol. 75 16 (2001) 7470-7480
29. Hu S.L., and Stamatatos L. Prospects of HIV Env modification as an approach to HIV vaccine design. Curr. HIV Res. 5 6 (2007) 507-513
30. Iyer S.P., Franti M., Krauchuk A.A., Fisch D.N., Ouattara A.A., Roux K.H., Krawiec L., Dey A.K., Beddows S., Maddon P.J., Moore J.P., and Olson W.C. Purified, proteolytically mature HIV type 1 SOSIP gp140 envelope trimers. AIDS Res. Hum. Retrovir. 23 6 (2007) 817-828
31. Karlsson Hedestam G.B., Fouchier R.A., Phogat S., Burton D.R., Sodroski J., and Wyatt R.T. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat. Rev., Microbiol. 6 2 (2008) 143-155
32. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., and Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393 6686 (1998) 648-659
33. Li Y., Migueles S.A., Welcher B., Svehla K., Phogat A., Louder M.K., Wu X., Shaw G.M., Connors M., Wyatt R.T., and Mascola J.R. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat. Med. 13 9 (2007) 1032-1034
34. Liu J., Bartesaghi A., Borgnia M.J., Sapiro G., and Subramaniam S. Molecular architecture of native HIV-1 gp120 trimers. Nature 455 7209 (2008) 109-113
35. Locher C.P., Heinrichs V., Apt D., and Whalen R.G. Overcoming antigenic diversity and improving vaccines using DNA shuffling and screening technologies. Expert Opin. Biol. Ther. 4 4 (2004) 589-597
36. Mascola J.R. Defining the protective antibody response for HIV-1. Curr. Mol. Med. 3 3 (2003) 209-216
37. Montefiori D., Sattentau Q., Flores J., Esparza J., and Mascola J. Antibody-based HIV-1 vaccines: recent developments and future directions. PLoS Med. 4 12 (2007) e348
38. Moore P.L., Crooks E.T., Porter L., Zhu P., Cayanan C.S., Grise H., Corcoran P., Zwick M.B., Franti M., Morris L., Roux K.H., Burton D.R., and Binley J.M. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J. Virol. 80 5 (2006) 2515-2528
39. Muster T., Steindl F., Purtscher M., Trkola A., Klima A., Himmler G., Ruker F., and Katinger H. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67 11 (1993) 6642-6647
40. Nishimura Y., Igarashi T., Haigwood N., Sadjadpour R., Plishka R.J., Buckler-White A., Shibata R., and Martin M.A. Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. J. Virol. 76 5 (2002) 2123-2130
41. Ofek G., Tang M., Sambor A., Katinger H., Mascola J.R., Wyatt R., and Kwong P.D. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J. Virol. 78 19 (2004) 10724-10737
42. Pancera M., and Wyatt R. Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage. Virology 332 1 (2005) 145-156
43. Pantophlet R., Ollmann Saphire E., Poignard P., Parren P.W., Wilson I.A., and Burton D.R. Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J. Virol. 77 1 (2003) 642-658
44. Pejchal R., Gach J.S., Brunel F.M., Cardoso R.M., Stanfield R.L., Dawson P.E., Burton D.R., Zwick M.B., and Wilson I.A. A conformational switch in HIV gp41 revealed by the structures of overlapping epitopes recognized by neutralizing antibodies. J. Virol. (2009)
45. Pilgrim A.K., Pantaleo G., Cohen O.J., Fink L.M., Zhou J.Y., Zhou J.T., Bolognesi D.P., Fauci A.S., and Montefiori D.C. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J. Infect. Dis. 176 4 (1997) 924-932
46. Pitisuttithum P., Gilbert P., Gurwith M., Heyward W., Martin M., van Griensven F., Hu D., Tappero J.W., and Choopanya K. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194 12 (2006) 1661-1671
47. Poignard P., Saphire E.O., Parren P.W., and Burton D.R. gp120: biologic aspects of structural features. Annu. Rev. Immunol. 19 (2001) 253-274
48. Poignard P., Moulard M., Golez E., Vivona V., Franti M., Venturini S., Wang M., Parren P.W., and Burton D.R. Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies. J. Virol. 77 1 (2003) 353-365
49. Prescott L.M., and Jones M.E. Modified methods for the determination of carbamyl aspartate. Anal. Biochem. 32 3 (1969) 408-419
50. Richman D.D., Wrin T., Little S.J., and Petropoulos C.J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. U.S.A. 100 7 (2003) 4144-4149
51. Roben P., Moore J.P., Thali M., Sodroski J., Barbas III C.F., and Burton D.R. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J. Virol. 68 8 (1994) 4821-4828
52. Sanders R.W., Vesanen M., Schuelke N., Master A., Schiffner L., Kalyanaraman R., Paluch M., Berkhout B., Maddon P.J., Olson W.C., Lu M., and Moore J.P. Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J. Virol. 76 17 (2002) 8875-8889
53. Saphire E.O., Parren P.W., Pantophlet R., Zwick M.B., Morris G.M., Rudd P.M., Dwek R.A., Stanfield R.L., Burton D.R., and Wilson I.A. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science 293 5532 (2001) 1155-1159
54. Sather D.N., Armann J., Ching L.K., Mavrantoni A., Sellhorn G., Caldwell Z., Yu X., Wood B., Self S., Kalams S., and Stamatatos L. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83 2 (2009) 757-769
55. Scanlan C.N., Pantophlet R., Wormald M.R., Ollmann Saphire E., Stanfield R., Wilson I.A., Katinger H., Dwek R.A., Rudd P.M., and Burton D.R. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1->2 mannose residues on the outer face of gp120. J. Virol. 76 14 (2002) 7306-7321
56. Schulke N., Vesanen M.S., Sanders R.W., Zhu P., Lu M., Anselma D.J., Villa A.R., Parren P.W., Binley J.M., Roux K.H., Maddon P.J., Moore J.P., and Olson W.C. Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein. J. Virol. 76 15 (2002) 7760-7776
57. Selvarajah S., Puffer B.A., Lee F.H., Zhu P., Li Y., Wyatt R., Roux K.H., Doms R.W., and Burton D.R. Focused dampening of antibody response to the immunodominant variable loops by engineered soluble gp140. AIDS Res. Hum. Retrovir. 24 2 (2008) 301-314
58. Sharma V.A., Kan E., Sun Y., Lian Y., Cisto J., Frasca V., Hilt S., Stamatatos L., Donnelly J.J., Ulmer J.B., Barnett S.W., and Srivastava I.K. Structural characteristics correlate with immune responses induced by HIV envelope glycoprotein vaccines. Virology (2006)
59. Sharon M., Kessler N., Levy R., Zolla-Pazner S., Gorlach M., and Anglister J. Alternative conformations of HIV-1 V3 loops mimic beta hairpins in chemokines, suggesting a mechanism for coreceptor selectivity. Structure (Camb). 11 2 (2003) 225-236
60. Shibata R., Igarashi T., Haigwood N., Buckler-White A., Ogert R., Ross W., Willey R., Cho M.W., and Martin M.A. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat. Med. 5 2 (1999) 204-210
61. Sougrat R., Bartesaghi A., Lifson J.D., Bennett A.E., Bess J.W., Zabransky D.J., and Subramaniam S. Electron tomography of the contact between T cells and SIV/HIV-1: implications for viral entry. PLoS Pathog. 3 5 (2007) e63
62. Srivastava I.K., Stamatatos L., Kan E., Vajdy M., Lian Y., Hilt S., Martin L., Vita C., Zhu P., Roux K.H., Vojtech L., D C.M., Donnelly J., Ulmer J.B., and Barnett S.W. Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate. J. Virol. 77 20 (2003) 11244-11259
63. Srivastava I.K., VanDorsten K., Vojtech L., Barnett S.W., and Stamatatos L. Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region. J. Virol. 77 4 (2003) 2310-2320
64. Trkola A., Purtscher M., Muster T., Ballaun C., Buchacher A., Sullivan N., Srinivasan K., Sodroski J., Moore J.P., and Katinger H. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70 2 (1996) 1100-1108
65. UNAIDS (2008). 2008 Report on the global AIDS epidemic Executive summary. UNAIDS. July 2008.
66. Voss G., Manson K., Montefiori D., Watkins D.I., Heeney J., Wyand M., Cohen J., and Bruck C. Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine. J. Virol. 77 2 (2003) 1049-1058
67. Walker B.D., and Burton D.R. Toward an AIDS vaccine. Science 320 5877 (2008) 760-764
68. Wyatt R., Kwong P.D., Desjardins E., Sweet R.W., Robinson J., Hendrickson W.A., and Sodroski J.G. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393 6686 (1998) 705-711
69. Yang X., Farzan M., Wyatt R., and Sodroski J. Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins. J. Virol. 74 12 (2000) 5716-5725
70. Yang X., Florin L., Farzan M., Kolchinsky P., Kwong P.D., Sodroski J., and Wyatt R. Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution. J. Virol. 74 10 (2000) 4746-4754
71. Yang X., Lee J., Mahony E.M., Kwong P.D., Wyatt R., and Sodroski J. Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J. Virol. 76 9 (2002) 4634-4642
72. Zanetti G., Briggs J.A., Grunewald K., Sattentau Q.J., and Fuller S.D. Cryo-electron tomographic structure of an immunodeficiency virus envelope complex in situ. PLoS Pathog. 2 8 (2006) e83
73. Zhang P.F., Cham F., Dong M., Choudhary A., Bouma P., Zhang Z., Shao Y., Feng Y.R., Wang L., Mathy N., Voss G., Broder C.C., and Quinnan Jr. G.V. Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization. Proc. Natl. Acad. Sci. U.S.A. 104 24 (2007) 10193-10198
74. Zhu P., Liu J., Bess Jr. J., Chertova E., Lifson J.D., Grise H., Ofek G.A., Taylor K.A., and Roux K.H. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 441 7095 (2006) 847-852
75. Zwick M.B., Labrijn A.F., Wang M., Spenlehauer C., Saphire E.O., Binley J.M., Moore J.P., Stiegler G., Katinger H., Burton D.R., and Parren P.W. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 75 22 (2001) 10892-10905